Cargando…
Diminished Functional Role and Altered Localization of Shp2 in Non-Small Cell Lung Cancer Cells With Egfr-Activating Mutations
Non-small cell lung cancer (NSCLC) cells harboring activating mutations of the epidermal growth factor receptor (EGFR) tend to display elevated activity of several survival signaling pathways. Surprisingly, these mutations also correlate with reduced phosphorylation of ERK and SHP2, a protein tyrosi...
Autores principales: | Furcht, Christopher M., Rojas, Andres Muñoz, Nihalani, Deepak, Lazzara, Matthew J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727284/ https://www.ncbi.nlm.nih.gov/pubmed/22777356 http://dx.doi.org/10.1038/onc.2012.240 |
Ejemplares similares
-
Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023) -
Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)
por: Karachaliou, Niki, et al.
Publicado: (2018) -
Dioscin overcome TKI resistance in EGFR-mutated lung adenocarcinoma cells via down-regulation of tyrosine phosphatase SHP2 expression
por: Wang, Yao-Chen, et al.
Publicado: (2018) -
Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer
por: Hu, Wentao, et al.
Publicado: (2017) -
NOTCH alteration in EGFR-mutated lung adenocarcinoma leads to histological small-cell carcinoma transformation under EGFR-TKI treatment
por: Koba, Hayato, et al.
Publicado: (2021)